|
With > 2 months of follow-up to allow for treatment
| |
|
N
|
285
|
|
%
|
87.7%
|
|
Receiving surgery within 4 months of diagnosis
| |
|
N
|
110
|
|
%
|
38.60%
|
|
Receiving radiation within 4 months of diagnosis
| |
|
N
|
91
|
|
%
|
31.93%
|
|
Receiving any medication
| |
|
N
|
212
|
|
%
|
74.4%
|
|
Type of treatment received (at any time post-index)
| |
|
Chemotherapy alone
|
15.1%
|
|
Aromatase Inhibitors (AI) therapy
| |
|
Anastrazole monotherapy
|
11.8%
|
|
Letrozole monotherapy
|
9.4%
|
|
Exmenestane monotherapy
|
1.4%
|
|
Multiple AI therapies
|
2.4%
|
|
Non-AI therapy
| |
|
Fulvestrant monotherapy
|
4.2%
|
|
Tamoxifen monotherapy
|
1.9%
|
|
Toremifene monotherapy
|
0.0%
|
|
Megestrol monotherapy
|
0.9%
|
|
Multiple non-AI therapies
|
0.5%
|
|
Chemotherapy combined with AI therapy
|
11.8%
|
|
Chemotherapy combined with non-AI therapy
|
15.1%
|
|
AI therapy combined with non-AI therapy
|
10.4%
|
|
Chemotherapy combined with AI and non-AI therapy
|
15.1%
|
|
Duration of any treatment (months)
| |
|
Mean ± SD
|
12.9 ± 9.1
|
|
Median
|
11.0
|
|
Duration of AI treatment (months), among those with any AI use
| |
|
Mean ± SD
|
11.0 ± 8.1
|
|
Median
|
9.5
|
|
Duration of non-AI treatment (months), among those with any non-AI use
|
|
Mean ± SD
|
5.6 ± 5.4
|
|
Median
|
4.0
|
|
Duration of chemo treatment (months), among those with any chemo use
|
|
Mean ± SD
|
8.5 ± 7.2
|
|
Median
|
6.0
|
